YM 150

Known as: YM-150, YM150 cpd 
 

Topic mentions per year

Topic mentions per year

2005-2013
01220052013

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Atrial fibrillation is a major risk factor for first and recurrent ischaemic stroke, and anticoagulation, mainly by use of… (More)
Is this relevant?
Review
2010
Review
2010
The oral Factor Xa inhibitor YM-150 is being developed by Astellas Pharma Inc for the prevention of venous thromboembolism (VTE… (More)
Is this relevant?
Review
2010
Review
2010
Currently, there are several lines of evidence supporting the interplay between coagulation and inflammation in the propagation… (More)
Is this relevant?
Review
2008
Review
2008
Advances in antithrombotic therapy began when traditional anticoagulant agents such as heparin and the vitamin K antagonists like… (More)
Is this relevant?
Review
2007
Review
2007
The antithrombotic management of venous thromboembolism (VTE) has gone through major developments. Indirect inhibitors such as… (More)
Is this relevant?
Review
2005
Review
2005
Venous thromboembolic disease, including deep vein thrombosis and pulmonary embolism, is a cause of significant mortality and… (More)
Is this relevant?